NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)
WOBURN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) — NeuroMetrix, Inc. (Nasdaq:NURO) reported the recent presentation of data from a clinical trial of Quell wearable neuromodulation technology in patients with post-acute COVID-19 syndrome (PACS), commonly called Long COVID. The presentation was made at the National Science Foundation (NSF) funded Center to Stream Healthcare In Place (C2SHIP) annual meeting in Washington DC. The trial was conducted at the Baylor College of Medicine in collaboration with C2SHIP. The principal investigator was Dr. Bijan Najafi, Professor of Surgery, and clinical director at the Division of Vascular Surgery and Endovascular Therapy, Baylor College of Medicine.
Related news for (NURO)
- electroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies
- electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness
- NeuroMetrix to be Acquired by electroCore
- NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024